<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04894760</url>
  </required_header>
  <id_info>
    <org_study_id>Rapid Test COVID</org_study_id>
    <nct_id>NCT04894760</nct_id>
  </id_info>
  <brief_title>Evaluation of a COVID-19 Rapid Diagnostic Test in ER Departments in Mexico: a Multi-center Study</brief_title>
  <official_title>Evaluation of a Rapid Diagnostic Test of SARS-COV-2 Carried Out in the Emergency Units of Reference Hospitals in Mexico and in Primary Care: Multi-center Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Respiratory Diseases, Mexico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Respiratory Diseases, Mexico</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observational (cross-sectional) study in the emergency services of participating&#xD;
      hospitals, receiving patients with COVID-19 and influenza, aiming to evaluate the diagnostic&#xD;
      performance of the rapid antigen detection test for COVID-19 both in nasal sampling and&#xD;
      saliva, in patients attending emergency services in the 2020-2021 winter season, performed on&#xD;
      site, compared to the gold standard (RT-qPCR).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study aims to analyze the usefulness of rapid tests, especially: a) as a diagnostic test&#xD;
      in people attending care for nonspecific, respiratory symptoms, in emergency services of&#xD;
      referral hospitals b) as a diagnostic test in contacts of known patients. c) as a diagnostic&#xD;
      test to differentiate influenza from COVID-19 in the circumstance of an overlap of both&#xD;
      viruses in the community. d) In the 3 cases, the gold standard would be the RT-PCR test for&#xD;
      influenza and for SARS-COV-2 performed in the usual laboratory following the officially&#xD;
      approved technique in Mexico. If the test were in saliva, it would also be much more accepted&#xD;
      and could come close to performing a test at home that would greatly facilitate the&#xD;
      diagnosis. So it is important to see the performance of a saliva test.&#xD;
&#xD;
      As an observational (cross-sectional) study in the emergency services of participating&#xD;
      hospitals, receiving patients with COVID-19 and influenza, aiming to evaluate the diagnostic&#xD;
      performance of the rapid antigen detection test for COVID-19 both in nasal sampling and&#xD;
      saliva, in patients attending emergency services in the 2020-2021 winter season, performed on&#xD;
      site, compared to the gold standard (RT-qPCR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 30, 2020</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic accuracy</measure>
    <time_frame>At 24 hours</time_frame>
    <description>Compared with gold standard RT-PCR</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Covid19</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Rapid Antigen Test (PanBio Ag test)</intervention_name>
    <description>Rapid Antigen Test (PanBio Ag test)</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Nasal swab sampling and Saliva testing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients that arrive to the ER department of each reference center.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Signed Informed consent&#xD;
&#xD;
          -  Emergency room visit or screening site with respiratory symptoms consistent with&#xD;
             COVID-19 / influenza.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Lactation&#xD;
&#xD;
          -  Decision of the responsible physician to remove patient from the study.&#xD;
&#xD;
          -  Transfer of the patient to another hospital unit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rogelio Perez-Padilla, MD</last_name>
    <phone>5551003780</phone>
    <email>perezpad@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ireri Thirion-Romero, MD. PhD.</last_name>
    <email>draisadora.thirion@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Instituto Nacional de Enfermedades Respiratorias, &quot;Ismael Cos√≠o Villegas&quot;</name>
      <address>
        <city>Mexico, City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ireri Thirion-romero, MD</last_name>
      <email>draisadora.thirion@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Rogelio Perez Padilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 12, 2021</study_first_submitted>
  <study_first_submitted_qc>May 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>May 24, 2021</last_update_submitted>
  <last_update_submitted_qc>May 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rapid test</keyword>
  <keyword>diagnosis</keyword>
  <keyword>antigen test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>No plan yet</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

